ZLAB - Zai Lab Limited
| Previous close | 59.12 |
| Open | 55.33 |
| Bid | 50.05 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 54.00 - 57.46 |
| 52-week range | 23.42 - 63.95 |
| Volume | 434,448 |
| Avg. volume | 342,877 |
| Market cap | 3.878B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.42 |
| Earnings date | 02 Sep 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.51 |
- GlobeNewswire
Zai Lab Announces Upcoming Participation at February Conferences
SHANGHAI, China and SAN FRANCISCO, Feb. 11, 2020 -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company,.
- Zacks
Will Zai Lab Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Zai Lab.
- GlobeNewswire
Zai Lab Announces Acceptance of NDA Submission of Omadacycline in China by the NMPA
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for omadacycline for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). “This is another important step in the development of Zai as a fully-integrated biopharmaceutical company,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.
- GlobeNewswire
Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies
Phase 1b Study of Niraparib in Combination with MGD013 in Advanced or Metastatic Gastric Cancer in ChinaRegistrational Bridging Study in China of Margetuximab plus Chemotherapy.
- GlobeNewswire
Zai Lab Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Greenshoe Option
SHANGHAI, China, and SAN FRANCISCO, Jan. 27, 2020 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage.
- GlobeNewswire
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
SHANGHAI, China, and SAN FRANCISCO, Jan. 22, 2020 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage.
- GlobeNewswire
Zai Lab Announces Proposed Public Offering of American Depositary Shares
SHANGHAI, China, and SAN FRANCISCO, Jan. 21, 2020 -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), a China and U.S.-based innovative commercial stage.
- GlobeNewswire
Zai Lab Appoints Lonnie Moulder to Board of Directors
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the appointment of Lonnie Moulder to its Board of Directors. "We are delighted to welcome Lonnie Moulder to our Board of Directors," said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab.
- GlobeNewswire
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety and efficacy of Tumor Treating Fields in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. “Zai Lab licensed Tumor Treating Fields from Novocure in September 2018, and we have since launched Optune® in Hong Kong for the treatment of patients with recurrent, or newly diagnosed glioblastoma multiforme (GBM) and submitted a Marketing Authorization Application to the China National Medical Products Administration (NMPA) for approval,” said Dr. Samantha Du, Founder and CEO of Zai Lab.
- Simply Wall St.
How Does Zai Lab Limited (NASDAQ:ZLAB) Affect Your Portfolio Volatility?
Anyone researching Zai Lab Limited (NASDAQ:ZLAB) might want to consider the historical volatility of the share price...
- GlobeNewswire
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the China National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. ZEJULA is a potent and highly selective PARP1/2 inhibitor that does not require BRCA mutation or other biomarker testing prior to administration.
- GlobeNewswire
Zai Lab Announces Upcoming Presentation at 38th Annual J.P. Morgan Healthcare Conference
SHANGHAI, China and SAN FRANCISCO, Dec. 23, 2019 -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company,.
- GlobeNewswire
Zai Lab Announces the Appointment of Timothy Yap, M.D., Ph.D., to its Scientific Advisory Board
SHANGHAI, China and SAN FRANCISCO, Dec. 16, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today.
- GlobeNewswire
Zai Lab Announces Upcoming Presentations at November Conferences
SHANGHAI, China and SAN FRANCISCO, Oct. 30, 2019 -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company,.
- GlobeNewswire
Zai Lab Partner, MacroGenics, Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
SHANGHAI, China and SAN FRANCISCO, Oct. 25, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today.
- GlobeNewswire
Zai Lab Partner, GSK, Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Expanded indication allows for treatment of women whose advanced ovarian cancer is associated with homologous recombination deficiency (HRD)Zejula is now the only, once-daily.
- GlobeNewswire
Dr. Samantha Du, Zai Lab Founder and CEO, to Participate in Forbes Global CEO Conference
SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today.
- GlobeNewswire
Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced its partner GlaxoSmithKline plc results from PRIMA (ENGOT-OV26/GOG-3012). PRIMA is a double-blind, randomized, placebo-controlled Phase 3 study of Zejula (niraparib) as a maintenance therapy in women with first-line ovarian cancer following a response to platinum-based chemotherapy.
- Simply Wall St.
Should Zai Lab (NASDAQ:ZLAB) Be Disappointed With Their 93% Profit?
Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...
Motley FoolZai Lab Limited (ZLAB) Q2 2019 Earnings Call Transcript
ZLAB earnings call for the period ending June 30, 2019.
- GlobeNewswire
Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019
-- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT-- SHANGHAI, China and SAN FRANCISCO, Sept. 03, 2019 -- Zai Lab Limited (“Zai Lab” or “the Company”).
- GlobeNewswire
Zai Lab Announces Publication of Pharmacokinetic Study of Niraparib in Chinese Ovarian Cancer Patients
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced publication of the open-label study evaluating the pharmacokinetic (PK) profile of niraparib in Chinese ovarian cancer patients. Results from the study show a PK profile of niraparib in Chinese patients comparable to that of patients evaluated in GSK’s global PK study. The study was published online in The Oncologist (DOI: 10.1634/theoncologist.2019-0565).
- GlobeNewswire
Zai Lab Announces Upcoming Presentations at September Conferences
SHANGHAI, China and SAN FRANCISCO, Aug. 26, 2019 -- Zai Lab Limited (“Zai Lab” or “the Company”) (NASDAQ: ZLAB), a China and US-based innovative commercial-stage.
- GlobeNewswire
Zai Lab to Report Financial Results for the Six Months Ended June 30, 2019 and Provide Corporate Update on September 3, 2019
SHANGHAI, China and SAN FRANCISCO, Aug. 20, 2019 -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today.
